Clinical Trials
232
69 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1977
Active, not recruiting
9
3.9%
Completed
17
7.3%
Enrolling By Invitation
1
0.4%
Not yet recruiting
59
25.4%
Recruiting
77
33.2%
Suspended
1
0.4%
Terminated
4
1.7%
Unknown
60
25.9%
Withdrawn
4
1.7%
No approval data available
- Lisaftoclax monotherapy achieved a 62.5% overall response rate and median progression-free survival of 23.89 months in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who had failed BTK inhibitors. - The phase 2 registrational study enrolled 77 patients with high-risk factors, including 42.9% with complex karyotype and 39% with del(17p)/TP53 mutations, representing an ultra-high-risk population. - The BCL-2 inhibitor demonstrated a manageable safety profile with no tumor lysis syndrome reported, supporting its conditional approval in China in July 2025. - Ascentage Pharma is conducting four global registrational Phase III trials to evaluate lisaftoclax in multiple hematologic malignancies including CLL/SLL, acute myeloid leukemia, and myelodysplastic syndrome.
- Two multi-institutional studies demonstrate that combining immune checkpoint inhibitors with total neoadjuvant therapy (TNT) achieves superior pathological complete response rates compared to standard chemoradiotherapy in microsatellite stable locally advanced rectal cancer patients. - The immunotherapy-enhanced TNT approach achieved complete response rates of 53.6% to 55.6%, significantly higher than historical controls, while maintaining acceptable toxicity profiles with grade 3-4 adverse events occurring in 43.2% of patients. - Both treatment sequencing strategies showed comparable long-term survival outcomes, with 3-year disease-free survival rates exceeding 80% and overall survival rates above 90%.
